117 related articles for article (PubMed ID: 19232485)
1. Interferon-alpha treatment may negatively influence disease progression in melanoma patients by hyperactivation of STAT3 protein.
Humpoliková-Adámková L; Kovařík J; Dušek L; Lauerová L; Boudný V; Fait V; Fojtová M; Krejčí E; Kovařík A
Eur J Cancer; 2009 May; 45(7):1315-1323. PubMed ID: 19232485
[TBL] [Abstract][Full Text] [Related]
2. Systemic interferon-alpha (IFN-alpha) treatment leads to Stat3 inactivation in melanoma precursor lesions.
Kirkwood JM; Farkas DL; Chakraborty A; Dyer KF; Tweardy DJ; Abernethy JL; Edington HD; Donnelly SS; Becker D
Mol Med; 1999 Jan; 5(1):11-20. PubMed ID: 10072444
[TBL] [Abstract][Full Text] [Related]
3. Lack of STAT 1 phosphorylation at TYR 701 by IFNgamma correlates with disease outcome in melanoma patients.
Boudny V; Dusek L; Adámková L; Chumchalová J; Kocak I; Fait V; Lauerová L; Krejcí E; Kovarík J
Neoplasma; 2005; 52(4):330-7. PubMed ID: 16059651
[TBL] [Abstract][Full Text] [Related]
4. Fluorescence imaging analysis of upstream regulators and downstream targets of STAT3 in melanoma precursor lesions obtained from patients before and after systemic low-dose interferon-alpha treatment.
Smith AP; Kirkwood JM; Edington HD; Jukic DM; Farkas DL; Becker D
Mol Imaging; 2003 Jan; 2(1):65-73. PubMed ID: 12926238
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of RIG-I mediated by ITGB3/c-SRC/STAT3 signaling confers resistance to interferon-α-induced apoptosis in tumor-repopulating cells of melanoma.
Li Y; Song Y; Li P; Li M; Wang H; Xu T; Yu X; Yu Y; Tai Y; Chen P; Cai X; Wang X; Xiang L; Deng R; Zhang X; Gao L; Wang X; Liu J; Cao F
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32152220
[TBL] [Abstract][Full Text] [Related]
6. Interferon-gamma inhibits interferon-alpha signalling in hepatic cells: evidence for the involvement of STAT1 induction and hyperexpression of STAT1 in chronic hepatitis C.
Radaeva S; Jaruga B; Kim WH; Heller T; Liang TJ; Gao B
Biochem J; 2004 Apr; 379(Pt 1):199-208. PubMed ID: 14690454
[TBL] [Abstract][Full Text] [Related]
7. Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNalpha2b.
Wang W; Edington HD; Rao UN; Jukic DM; Land SR; Ferrone S; Kirkwood JM
Clin Cancer Res; 2007 Mar; 13(5):1523-31. PubMed ID: 17332298
[TBL] [Abstract][Full Text] [Related]
8. STAT3 as a biomarker of progression in atypical nevi of patients with melanoma: dose-response effects of systemic IFNalpha therapy.
Wang W; Edington HD; Rao UN; Jukic DM; Wang H; Shipe-Spotloe JM; Kirkwood JM
J Invest Dermatol; 2008 Aug; 128(8):1997-2002. PubMed ID: 18305569
[TBL] [Abstract][Full Text] [Related]
9. STAT5 expression correlates with recurrence and survival in melanoma patients treated with interferon-α.
Machiraju D; Moll I; Gebhardt C; Sucker A; Buder-Bakhaya K; Schadendorf D; Hassel JC
Melanoma Res; 2018 Jun; 28(3):204-210. PubMed ID: 29485532
[TBL] [Abstract][Full Text] [Related]
10. Expression of STAT1 and STAT2 in malignant melanoma does not correlate with response to interferon-alpha adjuvant therapy.
Lesinski GB; Valentino D; Hade EM; Jones S; Magro C; Chaudhury AR; Walker MJ; Carson WE
Cancer Immunol Immunother; 2005 Sep; 54(9):815-25. PubMed ID: 15668815
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of p-STAT3 enhances IFN-alpha efficacy against metastatic melanoma in a murine model.
Kong LY; Gelbard A; Wei J; Reina-Ortiz C; Wang Y; Yang EC; Hailemichael Y; Fokt I; Jayakumar A; Qiao W; Fuller GN; Overwijk WW; Priebe W; Heimberger AB
Clin Cancer Res; 2010 May; 16(9):2550-61. PubMed ID: 20388845
[TBL] [Abstract][Full Text] [Related]
12. Melanoma cells exhibit variable signal transducer and activator of transcription 1 phosphorylation and a reduced response to IFN-alpha compared with immune effector cells.
Lesinski GB; Trefry J; Brasdovich M; Kondadasula SV; Sackey K; Zimmerer JM; Chaudhury AR; Yu L; Zhang X; Crespin TR; Walker MJ; Carson WE
Clin Cancer Res; 2007 Sep; 13(17):5010-9. PubMed ID: 17785551
[TBL] [Abstract][Full Text] [Related]
13. Interferon-alpha induced Raynaud's syndrome.
Kruit WH; Eggermont AM; Stoter G
Ann Oncol; 2000 Nov; 11(11):1501-2. PubMed ID: 11142493
[TBL] [Abstract][Full Text] [Related]
14. Interferon Alpha Signalling and Its Relevance for the Upregulatory Effect of Transporter Proteins Associated with Antigen Processing (TAP) in Patients with Malignant Melanoma.
Heise R; Amann PM; Ensslen S; Marquardt Y; Czaja K; Joussen S; Beer D; Abele R; Plewnia G; Tampé R; Merk HF; Hermanns HM; Baron JM
PLoS One; 2016; 11(1):e0146325. PubMed ID: 26735690
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of interferon-gamma-stimulated melanoma progression by targeting neuronal nitric oxide synthase (nNOS).
Tong S; Cinelli MA; El-Sayed NS; Huang H; Patel A; Silverman RB; Yang S
Sci Rep; 2022 Feb; 12(1):1701. PubMed ID: 35105915
[TBL] [Abstract][Full Text] [Related]
16. Multiparametric flow cytometric analysis of inter-patient variation in STAT1 phosphorylation following interferon Alfa immunotherapy.
Lesinski GB; Kondadasula SV; Crespin T; Shen L; Kendra K; Walker M; Carson WE
J Natl Cancer Inst; 2004 Sep; 96(17):1331-42. PubMed ID: 15339971
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study.
Grob JJ; Jouary T; Dréno B; Asselineau J; Gutzmer R; Hauschild A; Leccia MT; Landthaler M; Garbe C; Sassolas B; Herbst RA; Guillot B; Chene G; Pehamberger H
Eur J Cancer; 2013 Jan; 49(1):166-74. PubMed ID: 22975216
[TBL] [Abstract][Full Text] [Related]
18. High LIFr expression stimulates melanoma cell migration and is associated with unfavorable prognosis in melanoma.
Guo H; Cheng Y; Martinka M; McElwee K
Oncotarget; 2015 Sep; 6(28):25484-98. PubMed ID: 26329521
[TBL] [Abstract][Full Text] [Related]
19. Malignant melanoma associates with deficient IFN-induced STAT 1 phosphorylation.
Kovarik J; Boudny V; Kocak I; Lauerova L; Fait V; Vagundova M
Int J Mol Med; 2003 Sep; 12(3):335-40. PubMed ID: 12883649
[TBL] [Abstract][Full Text] [Related]
20. "Activated" STAT proteins: a paradoxical consequence of inhibited JAK-STAT signaling in cytomegalovirus-infected cells.
Trilling M; Le VT; Rashidi-Alavijeh J; Katschinski B; Scheller J; Rose-John S; Androsiac GE; Jonjic S; Poli V; Pfeffer K; Hengel H
J Immunol; 2014 Jan; 192(1):447-58. PubMed ID: 24319264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
